In multiple myeloma patients receiving either one of the COVID-19 mRNA vaccines or the vector-based vaccine AZD1222, treatment with anti-CD38 monoclonal antibodies or anti-BCMA ADCs was associated with significantly reduced humoral vaccine response [113,114]. This evidence concerns the gene CD38 and plasma cell myeloma.